Binimetinib is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Binimetinib was developed by Array Biopharma Inc.
The API has now reached off-patent status, after being launched in 2018.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Binimetinib was exported from India in 2023 , with an average price over the period of $76930 /kg.
The key suppliers were MSN Laboratories, with a focus on markets in North America.

For enquiries regarding more detailed trade data of Binimetinib and many others, contact info@pharmacheminvestor.com